Lipoid Proteinozisin Nörobiyolojik Etkileri: Fosforile Tau, S100B, NSE, NEFL ve GFAP Üzerine Bir Araştırma

Year 2024, , 287 - 292, 29.08.2024

Seyhan Taşkın , Hakim Çelik , Mustafa Aksoy

https://doi.org/10.35440/hutfd.1510899

Abstract

Amaç: Urbach-Wiethe hastalığı olarak da adlandırılan Lipoid Proteinozis (LP), hiyalin materyalinin sistemik olarak birikmesiyle belirginleşen bir genodermatozdur. Etiyolojisi ECM1 mutasyonlarına da-yanan LP'nin nöropatolojik spektrumunun, önemli nörobiyolojik etkilerin potansiyelinin altını çizen bir dizi nörodejeneratif biyobelirteç içerdiği varsayılmıştır. Bu çalışma, LP hastalarında nörodejeneratif biyobelirteçlerin (fosforile Tau (pMAPT) S100B, Nöron Spesifik Enolaz (NSE), Nörofilament Hafif Zincir (NEFL) ve Glial Fibriller Asidik Protein (GFAP) ) serum konsantrasyonlarını ölçmeyi ve bu belirteçlerin tanısal potasiyellerini belirlemeyi amaçladı.
Materyal ve Metod: 15 LP'li hasta ve 15 sağlıklı kontrol çalışmaya dahil edildi. Nörodejeneratif biyobe-lirteçlerin serum seviyeleri ELISA testleri kullanılarak ölçüldü ve prediktif güçleri ikili lojistik regresyon ve Receiver Operating Characteristic (ROC) analizi yoluyla değerlendirildi.
Bulgular: LP hastalarında sağlıklı kontrollere göre NSE, NEFL ve GFAP serum düzeyleri daha yüksekti ve bu artışın istatistiksel olarak anlamlı olduğu bulundu (p<0.05). Buna karşılık, pMAPT ve S100B seviyele-rinde anlamlı farklılık gözlenmedi. GFAP'nin, 0.813'lük eğri altında kalan alan (AUC) değeri ve 0.658-0.968'lik %95 güven aralığı (CI) ile LP için prediktif bir belirteç olabileceği düşünülmektedir (p=0.003).
Sonuç: Bu sonuçlar NSE, NEFL ve GFAP konsantrasyonlarının LP’de önemli ölçüde arttığını göstermekte ve LP'de belirgin bir nörodejeneratif profilin altını çizmektedir. Bu biyobelirteçler, özellikle GFAP, LP için yeni bir indikatör olabilir ve ileriye yönelik biyobelirteç bazlı tanı stratejileri sunabilir. Bu çalış-mada elde edilen bilgiler, gelecekteki yüksek etkili araştırmalar için yeni bir yol çizerek LP'nin anlaşıl-ması ve klinik yönetiminde yol gösterici olacaktır.

Keywords

Lipoid Proteinozis, Nörodejenerasyon, Biyobelirteçler, Tanısal Nöroloji, ECM1

Project Number

-

Neurobiological Effects of Lipoid Proteinosis: A Study on Phosphorylated Tau, S100B, NSE, NEFL, and GFAP

Abstract

Background: Lipoid Proteinosis (LP), also termed Urbach-Wiethe disease, is an enigmatic genodermato-sis marked by the systemic deposition of hyaline material. With its etiology rooted in ECM1 mutations, LP’s neuropathological spectrum has been hypothesized to involve an array of neurodegenerative biomarkers, underscoring a potential for substantial neurobiological implications. This study endeav-ored to elucidate the serum concentrations of neurodegenerative biomarkers—phosphorylated Tau (pMAPT), S100B, Neuron-Specific Enolase (NSE), Neurofilament Light Chain (NEFL), and Glial Fibrillary Acidic Protein (GFAP)—in LP patients, seeking to establish their diagnostic utility for the condition.
Materials and Methods: Fifteen LP patients and 15 matched healthy controls were enrolled. Serum levels of the biomarkers were quantified using ELISA, and their predictive power was assessed through binary logistic regression and Receiver Operating Characteristic (ROC) analysis.
Results: Elevated serum levels of NSE, NEFL, and GFAP were observed in LP subjects relative to healthy counterparts, reaching statistical significance (p<0.05). In contrast, pMAPT and S100B levels did not differ appreciably. GFAP is considered a predictive marker for LP with an area under the curve (AUC) value of 0.813 and a 95% confidence interval (CI) of 0.658-0.968 (p=0.003).
Conclusions: The study underscores a distinctive neurodegenerative profile in LP, with NSE, NEFL, and GFAP concentrations significantly amplified. These biomarkers, particularly GFAP, may represent novel indicators for LP, offering prospective biomarker-based diagnostic strategies. The insights garnered herein pave the way for advanced understanding and clinical management of LP, delineating a novel avenue for future high-impact research.

Keywords

Lipoid Proteinosis, Neurodegeneration, Biomarkers, Diagnostic Neurology, ECM1

Ethical Statement

The study protocol adhered to the ethical standards established by the Declaration of Helsinki and Good Clinical Practice guidelines, and received approval from the Clinical Research Ethics Committee of Harran University (HRU/23.24.26).

Supporting Institution

-

Project Number

-

Thanks

-

References

• 1. An İ, Aksoy M, Öztürk M, Ayhan E. Lipoid proteinosis. Mucosa. 2021;4(2):30-40. doi:10.33204/mucosa.936953
• 2. Varghese AM, Syed KA, Sivaranjini R. Lipoid Protei-nosis—A Pediatric Otolaryngologist’s Perspective: A Case Report and Review of Literature. An Internatio-nal Journal of Otorhinolaryngology Clinics. 2015;7(2):97-99. doi:10.5005/jp-journals-10003-1201
• 3. Hamada T, Wessagowit V, South AP, Ashton GH, Chan I, Oyama N, et al. Extracellular Matrix Protein 1 Gene (ECM1) Mutations in Lipoid Proteinosis and Genoty-pe-Phenotype Correlation. Journal of Investigative Dermatology. 2003;120(3):345-350. doi:10.1046/j.1523-1747.2003.12073.x
• 4. Appenzeller S, Chaloult E, Velho P, de Souza EM, Araújo VZ, Cendes F, et al. Amygdalae Calcifications Associated with Disease Duration in Lipoid Protei-nosis. Journal of Neuroimaging. 2006;16(2):154-156. doi:10.1111/j.1552-6569.2006.00018.x
• 5. Custódio Lima J, Nagasako CK, Montes CG, Barcelos IHK, de Carvalho RB, Mesquita MA. Gastrointestinal Involvement in Lipoid Proteinosis: A Ten-Year Follow-Up of a Brazilian Female Patient. Case Rep Med. 2014;2014:1-4. doi:10.1155/2014/952038
• 6. Mukherjee B, Devi P. Lipoid proteinosis: A rare en-tity. Indian J Ophthalmol. 2015;63(8):680. doi:10.4103/0301-4738.169791
• 7. Han B, Zhang X, Liu Q, Chen X, Zhu X. Homozygous Missense Mutation in the ECM1 Gene in Chinese Sib-lings with Lipoid Proteinosis. Acta Derm Venereol. 2007;87(5):387-389. doi:10.2340/00015555-0292
• 8. Sercu S, Zhang M, Oyama N, Hansen U, Ghalbzouri AE, Jun G, et al. Interaction of extracellular matrix protein 1 with extracellular matrix components: ECM1 is a basement membrane protein of the skin. J Invest Dermatol. 2008;128(6):1397-408.
• 9. Brar BK, Jain S, Brar SK. Lipoid proteinosis: A case with distinct histopathological and radiological fin-dings. J Cutan Pathol. 2017;44(10):887-891. doi:10.1111/cup.13002
• 10. Gonçalves FG, de Melo MB, de L Matos V, Barra FR, Figueroa RE. Amygdalae and striatum calcification in lipoid proteinosis. AJNR Am J Neuroradiol. 2010;31:88-90.
• 11. Mcgrath JA. Lipoid proteinosis. Handb Clin Neurol. 2015;132:317-22.
• 12. Oguz Akarsu E, Dinçsoy Bir F, Baykal C, Taşdemir V, Kara B, Bebek N, et al. The Characteristics and Long-Term Course of Epilepsy in Lipoid Proteinosis: A Spectrum From Mild to Severe Seizures in Relation to ECM1 Mutations. Clin EEG Neurosci. 2018 May;49(3):192-196.
• 13. Iqbal K, Liu F, Gong CX, Alonso A del C, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol. 2009;118(1):53-69. doi:10.1007/s00401-009-0486-3
• 14. Moloney CM, Labuzan SA, Crook JE, Siddiqui H, Casta-nedes-Casey M, Lachner C, et al. Phosphorylated tau sites that are elevated in Alzheimer’s disease fluid bi-omarkers are visualized in early neurofibrillary tangle maturity levels in the post mortem brain. Alzheimer’s & Dementia. 2023;19(3):1029-1040. doi:10.1002/alz.12749
• 15. Liang M, Zhang L, Geng Z. Advances in the Develop-ment of Biomarkers for Poststroke Epilepsy. Biomed Res Int. 2021;2021:1-8. doi:10.1155/2021/5567046
• 16. Posti JP, Tenovuo O. Blood‐based biomarkers and traumatic brain injury—A clinical perspective. Acta Neurol Scand. 2022;146(4):389-399.
• 17. Takeuchi A, Miyaishi O, Kiuchi K, Isobe K. Macrophage colony‐stimulating factor is expressed in neuron and microglia after focal brain injury. J Neurosci Res. 2001;65(1):38-44. doi:10.1002/jnr.1125
• 18. Wang S, Ji D, Yang Q, Li M, Ma Z, Zhang S, et al. NEFLb impairs early nervous system development via regu-lation of neuron apoptosis in zebrafish. J Cell Physiol. 2019;234(7):11208-11218. doi:10.1002/jcp.27771
• 19. Spotorno N, Lindberg O, Nilsson C, Landqvist Waldö M, van Westen D, Nilsson K, et al. Plasma neurofila-ment light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia. PLoS One. 2020;15(10):e0236384. doi:10.1371/journal.pone.0236384
• 20. Sereika M, Urbanaviciute R, Tamasauskas A, Skiriute D, Vaitkiene P. GFAP expression is influenced by ast-rocytoma grade and rs2070935 polymorphism. J Can-cer. 2018;9(23):4496-4502. doi:10.7150/jca.26769
• 21. Chatterjee P, Vermunt L, Gordon BA, Pedrini S, Boon-kamp L, Armstrong NJ, et al. Plasma glial fibrillary aci-dic protein in autosomal dominant Alzheimer’s disea-se: Associations with Aβ‐PET, neurodegeneration, and cognition. Alzheimer’s & Dementia. 2023;19(7):2790-2804. doi:10.1002/alz.12879
• 22. Nagy V, Bozdagi O, Matynia A, Balcerzyk M, Okulski P, Dzwonek J, et al. Matrix metalloproteinase-9 is requi-red for hippocampal late-phase long-term potentia-tion and memory. J Neurosci 2006;26:1923–1934.
• 23. Mondejar R, Garcia-Moreno JM, Rubio R, Solano F, Delgado M, Garcia-Bravo B,et al. Clinical and Molecu-lar Study of the Extracellular Matrix Protein 1 Gene in a Spanish Family with Lipoid Proteinosis. J Clin Neurol. 2014 Jan;10(1):64-68.
• 24. Pan B, Lu X, Han X, Huan J, Gao D, Cui S, et al. Mecha-nism by Which Aluminum Regulates the Abnormal Phosphorylation of the Tau Protein in Different Cell Lines. ACS Omega. 2021;6(47):31782-31796. doi:10.1021/acsomega.1c04434
• 25. Brozzi F, Arcuri C, Giambanco I, Donato R. S100B Pro-tein Regulates Astrocyte Shape and Migration via In-teraction with Src Kinase. Journal of Biological Che-mistry. 2009;284(13):8797-8811. doi:10.1074/jbc.M805897200
• 26. Lian D, Chen T, Yan L, Hou H, Gao S, Hu Q, et al. Pro-tective effect of compatible herbs in Jin-Gu-Lian for-mula against Alangium chinense-induced neuro-toxicity via oxidative stress, neurotransmitter meta-bolisms, and pharmacokinetics. Front Pharmacol. 2023;14. doi:10.3389/fphar.2023.1133982
• 27. Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D’Anna L, Huss A, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18(3):158-172. doi:10.1038/s41582-021-00616-3